Pirfenidone in Heart Failure with Preserved Ejection Fraction-Rationale and Design of the PIROUETTE Trial

Lewis, Gavin A, Schelbert, Erik B, Naish, Josephine H, Bedson, Emma, Dodd, Susanna ORCID: 0000-0003-2851-3337, Eccleson, Helen, Clayton, Dannii ORCID: 0000-0003-3535-3466, Jimenez, Beatriz Duran, McDonagh, Theresa, Williams, Simon G
et al (show 8 more authors) (2019) Pirfenidone in Heart Failure with Preserved Ejection Fraction-Rationale and Design of the PIROUETTE Trial. CARDIOVASCULAR DRUGS AND THERAPY, 33 (4). pp. 461-470.

Access the full-text of this item by clicking on the Open Access link.


<h4>Background</h4>The PIROUETTE (PIRfenidOne in patients with heart failUre and preserved lEfT venTricular Ejection fraction) trial is designed to evaluate the efficacy and safety of the anti-fibrotic pirfenidone in patients with chronic heart failure and preserved ejection fraction (HFpEF) and myocardial fibrosis. HFpEF is a diverse syndrome associated with substantial morbidity and mortality. Myocardial fibrosis is a key pathophysiological mechanism of HFpEF and myocardial fibrotic burden is strongly and independently associated with adverse outcome. Pirfenidone is an oral anti-fibrotic agent, without haemodynamic effect, that leads to regression of myocardial fibrosis in preclinical models. It has proven clinical effectiveness in pulmonary fibrosis.<h4>Methods</h4>The PIROUETTE trial is a randomised, double-blind, placebo-controlled phase II trial evaluating the efficacy and safety of 52 weeks of treatment with pirfenidone in patients with chronic HFpEF (symptoms and signs of heart failure, left ventricular ejection fraction ≥ 45%, elevated natriuretic peptides [BNP ≥ 100 pg/ml or NT-proBNP ≥ 300 pg/ml; or BNP ≥ 300 pg/ml or NT-proBNP ≥ 900 pg/ml if in atrial fibrillation]) and myocardial fibrosis (extracellular matrix (ECM) volume ≥ 27% measured using cardiovascular magnetic resonance). The primary outcome measure is change in myocardial ECM volume. A sub-study will investigate the relationship between myocardial fibrosis and myocardial energetics, and the impact of pirfenidone, using <sup>31</sup>phosphorus magnetic resonance spectroscopy.<h4>Discussion</h4>PIROUETTE will determine whether pirfenidone is superior to placebo in relation to regression of myocardial fibrosis and improvement in myocardial energetics in patients with HFpEF and myocardial fibrosis (NCT02932566).<h4>Clinical trial registration</h4>clinicaltrials.gov (NCT02932566) https://clinicaltrials.gov/ct2/show/NCT02932566.

Item Type: Article
Uncontrolled Keywords: Fibrosis, Heart failure, Magnetic resonance imaging (MRI)
Depositing User: Symplectic Admin
Date Deposited: 28 May 2019 12:45
Last Modified: 19 Jan 2023 00:42
DOI: 10.1007/s10557-019-06876-y
Open Access URL: https://doi.org/10.1007/s10557-019-06876-y
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3043365